What pharmacologic sleep aids are appropriate for occasional insomnia, including dosing and safety considerations?

Pharmacologic Sleep Aids for Occasional Insomnia

For occasional insomnia in adults, use eszopiclone (3 mg), zolpidem (5-10 mg), or suvorexant (10-20 mg) as first-line prescription options, with over-the-counter prolonged-release melatonin (2 mg) being the most evidence-supported non-prescription alternative for older adults. 1, 2

Prescription Sleep Aids

First-Line FDA-Approved Options

The American College of Physicians guideline identifies three medications with the strongest evidence for short-term efficacy 1:

• Zolpidem: 10 mg for non-elderly adults, 5 mg for elderly or women

  • Immediate-release reduces sleep latency within 45-60 minutes
  • Half-life of 2.4 hours minimizes morning hangover
  • Extended-release (6.25-12.5 mg) improves sleep maintenance over 6 hours 3

• Eszopiclone: 1-3 mg dosing

  • Improves both sleep onset and maintenance
  • Longer duration of action than zolpidem

• Suvorexant: 10-20 mg (orexin receptor antagonist)

  • Works by blocking wakefulness rather than inducing sedation
  • Lower abuse potential and no withdrawal or rebound insomnia 4
  • Newer DORAs (daridorexant, lemborexant) show similar efficacy with 8-hour half-lives 4, 5

Alternative Prescription Options

• Low-dose doxepin: 3-6 mg (antihistamine effect)

  • Particularly effective for sleep maintenance in the last third of the night 6, 5
  • Among the most effective with good tolerability profile

• Ramelteon: Melatonin receptor agonist

  • Reduces sleep onset latency by 7-12 minutes 5

Over-the-Counter Options

Evidence-Supported

Prolonged-release melatonin is the only OTC agent with consistent evidence 2:

• Most effective in older adults (age >55)
• Improves sleep onset and quality
• Favorable safety profile
• Immediate-release formulations show limited benefit

Limited Evidence

• Diphenhydramine: Lacks robust clinical evidence despite widespread use 2
• Doxylamine: May help maintenance insomnia but requires better dosing guidance 6
• Valerian: Inconsistent evidence, though some studies show promise 2, 7

Critical Safety Considerations

FDA-Documented Risks (All Prescription Hypnotics) 1

• Cognitive and behavioral changes including next-day driving impairment
• Dose reduction required in women and elderly
• Observational data links chronic use to increased dementia, fractures, and major injury risk

Dosing Algorithm

1. Women and elderly (>65): Start with lowest available dose (zolpidem 5 mg, eszopiclone 1 mg)
2. Non-elderly adults: Standard dosing acceptable
3. Sleep onset problems: Immediate-release formulations or ramelteon
4. Sleep maintenance problems: Extended-release formulations, doxepin 3-6 mg, or DORAs

Common Pitfalls

• Avoid benzodiazepines: Insufficient evidence for efficacy in insomnia despite historical use 1
• Don't rely on antihistamines: Diphenhydramine lacks quality evidence despite OTC popularity 2
• Limit duration: All evidence is for short-term use; long-term efficacy unknown 1
• Screen for comorbidities: Treat insomnia as distinct disorder even when comorbid conditions exist 4

The absolute effect sizes for all pharmacologic agents are small, with improvements in total sleep time of 20-35 minutes and sleep latency reductions of 7-12 minutes compared to placebo 1, 5. This modest benefit must be weighed against potential harms, particularly with chronic use.